Author

C. Manelfi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1 Assay:structural biology· 1 Organism:virus· 1

Frequent Co-Authors

A. R. Beccari· 2 shared C. Talarico· 2 shared A. Caruso· 1 shared A. Hanke· 1 shared A. Zaliani· 1 shared B. P. Joseph· 1 shared C. Bergh· 1 shared D. B. Kokh· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. R. Beccari

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Characterization of raloxifene as potential pharmacological agent against SARS-CoV-2 and its variants

D. Iaconis, C. Talarico, C. Manelfi, M. C. Cesta, M. Zippoli, F. Caccuri, G. Matusali, L. Bordi, L. Scorzolini, E. M. Bucci, A. Caruso, E. Nicastri, M. Allegretti, A. R. Beccari

This paper identifies raloxifene as a potential drug candidate for treating COVID-19 through virtual screening and pharmacological characterization across multiple viral variants.

bioRxiv · Oct 22, 2021Pharmacology & Toxicology

A blueprint for high affinity SARS-CoV-2 Mpro inhibitors from activity-based compound library screening guided by analysis of protein dynamics

J. Gossen, S. Albani, A. Hanke, B. P. Joseph, C. Bergh, M. Kuzikov, E. Costanza, C. Manelfi, P. Storici, P. Gribbon, A. R. Beccari, C. Talarico, F. Spyrakis, E. Lindahl, A. Zaliani, , G. Rossetti

The paper identifies a blueprint for high affinity SARS-CoV-2 Mpro inhibitors by analyzing protein dynamics and redefining druggability through virtual screening and pharmacophore modeling.

bioRxiv · Dec 14, 2020Biophysics